BDX
Becton, Dickinson and Company NYSE Listed Feb 21, 1973$153.21
After hrs
$149.33
-0.07%
Mkt Cap $55.5B
52w Low $127.59
42.9% of range
52w High $187.35
50d MA $158.29
200d MA $154.32
P/E (TTM)
25.6x
EV/EBITDA
10.4x
P/B
1.7x
Debt/Equity
0.8x
ROE
7.0%
P/FCF
12.4x
RSI (14)
—
ATR (14)
—
Beta
0.35
50d MA
$158.29
200d MA
$154.32
Avg Volume
2.9M
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
1 Becton Drive · Franklin Lakes, NJ 07417-1880 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | TNS | 2.78 | 2.90 | +4.3% | — | — | — | — | — | — | — | — |
| Feb 9, 2026 | TNS | 2.21 | 2.91 | +31.7% | 162.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% | — |
| Nov 6, 2025 | TNS | 3.92 | 3.96 | +1.0% | 109.63 | -0.2% | +0.3% | +2.4% | +6.6% | +8.3% | +8.8% | — |
| Aug 7, 2025 | TNS | 3.40 | 3.68 | +8.2% | 115.99 | -0.4% | +3.1% | +2.6% | +3.9% | +4.4% | +3.9% | — |
| May 1, 2025 | TNS | 3.28 | 3.35 | +2.1% | 104.79 | +1.0% | -0.4% | -1.5% | -2.6% | -1.4% | -0.9% | — |
| Feb 5, 2025 | TNS | 3.00 | 3.43 | +14.3% | 151.46 | -4.7% | -7.3% | -6.2% | -6.3% | -6.3% | -7.8% | — |
| Nov 7, 2024 | TNS | 3.77 | 3.81 | +1.1% | 140.37 | +0.7% | +2.0% | +3.3% | +1.8% | +1.8% | +0.0% | — |
| Aug 1, 2024 | TNS | 3.31 | 3.50 | +5.7% | 145.86 | +0.4% | +2.5% | -0.1% | -0.2% | -1.4% | -0.7% | — |
| May 2, 2024 | TNS | 2.97 | 3.17 | +6.7% | 148.54 | -0.7% | -2.3% | -1.6% | -1.3% | -2.8% | -2.2% | — |
| Feb 1, 2024 | TNS | 2.40 | 2.68 | +11.7% | 149.79 | +1.0% | -2.1% | -3.0% | -1.5% | -1.2% | -0.7% | — |
| Nov 9, 2023 | TNS | 3.42 | 3.42 | +0.0% | 143.55 | +0.7% | +1.0% | +1.5% | +0.5% | +0.6% | +1.2% | — |
| Aug 3, 2023 | TNS | 2.89 | 2.96 | +2.4% | 166.07 | -0.2% | +0.8% | +2.4% | +4.6% | +4.8% | +3.2% | — |
| May 4, 2023 | AMC | 2.75 | 2.86 | +4.0% | 156.04 | +0.8% | +0.5% | -0.4% | -1.1% | -0.6% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Evercore ISI | Reiterates | Outperform | $180 | $149.31 | $149.00 | -0.2% | -2.0% | -3.4% | -3.0% | +2.6% | — |
| Apr 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $154.82 | $155.41 | +0.4% | +2.4% | +2.5% | +1.2% | +0.5% | +0.0% |
| Mar 26 | Piper Sandler | Maintains | Neutral → Neutral | — | $158.27 | $156.83 | -0.9% | -0.6% | -2.4% | -2.3% | -0.7% | -1.2% |
| Mar 23 | Argus | Maintains | Buy → Buy | — | $154.13 | $156.68 | +1.7% | +1.4% | +1.2% | +2.7% | +2.1% | +0.2% |
| Feb 11 | Citigroup | Maintains | Buy → Buy | — | $171.68 | $170.67 | -0.6% | +5.2% | +3.6% | +2.5% | +3.3% | +6.4% |
| Feb 10 | JP Morgan | Maintains | Neutral → Neutral | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Jefferies | Maintains | Buy → Buy | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Citigroup | Maintains | Buy → Buy | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Jan 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $159.84 | $160.35 | +0.3% | -0.7% | -1.1% | +0.1% | -0.7% | +1.5% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $161.45 | $161.48 | +0.0% | -1.3% | -0.1% | -1.3% | -1.3% | -1.9% |
| Jan 5 | BofA Securities | Maintains | Neutral → Neutral | — | $153.25 | $152.61 | -0.4% | +2.1% | +5.4% | +4.0% | +5.3% | +4.0% |
| Dec 17 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $154.40 | $154.12 | -0.2% | -0.5% | -0.9% | -0.4% | +0.2% | -0.4% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $150.80 | $151.42 | +0.4% | -0.7% | +0.9% | +1.0% | +1.1% | -1.2% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $109.63 | $109.37 | -0.2% | +0.3% | +2.4% | +6.6% | +8.3% | +8.8% |
| Nov 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $109.63 | $109.37 | -0.2% | +0.3% | +2.4% | +6.6% | +8.3% | +8.8% |
| Oct 16 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $115.43 | $112.99 | -2.1% | -0.8% | +1.2% | +2.3% | +1.2% | +0.7% |
| Aug 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $119.59 | $119.62 | +0.0% | -0.5% | +0.8% | +1.3% | +0.8% | +1.3% |
| Aug 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $115.99 | $115.50 | -0.4% | +3.1% | +2.6% | +3.9% | +4.4% | +3.9% |
| Aug 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $115.99 | $115.50 | -0.4% | +3.1% | +2.6% | +3.9% | +4.4% | +3.9% |
| Jun 3 | Barclays | Maintains | Overweight → Overweight | — | $104.70 | $104.28 | -0.4% | +0.7% | +0.9% | +1.0% | +2.4% | +1.8% |
| May 22 | Citigroup | Downgrade | Buy → Neutral | — | $107.01 | $105.72 | -1.2% | -0.5% | -1.0% | +0.8% | -0.1% | +0.4% |
| May 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $103.22 | $103.02 | -0.2% | -1.1% | +0.1% | +0.6% | +0.1% | +5.0% |
| May 2 | Piper Sandler | Downgrade | Overweight → Neutral | — | $104.79 | $105.86 | +1.0% | -0.4% | -1.5% | -2.6% | -1.4% | -0.9% |
| May 2 | Stifel | Maintains | Buy → Buy | — | $104.79 | $105.86 | +1.0% | -0.4% | -1.5% | -2.6% | -1.4% | -0.9% |
| May 1 | William Blair | Downgrade | Outperform → Market Perform | — | $128.00 | $116.10 | -9.3% | -18.1% | -18.5% | -19.4% | -20.3% | -19.3% |
| May 1 | Citigroup | Maintains | Buy → Buy | — | $128.00 | $116.10 | -9.3% | -18.1% | -18.5% | -19.4% | -20.3% | -19.3% |
| Apr 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $123.54 | $125.20 | +1.3% | +1.2% | +2.3% | +2.6% | +2.4% | +3.3% |
| Apr 7 | Barclays | Maintains | Overweight → Overweight | — | $128.14 | $126.56 | -1.2% | -1.1% | -3.1% | +1.0% | -4.0% | -2.7% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $139.06 | $140.45 | +1.0% | -0.1% | +0.1% | +1.1% | +1.3% | +1.1% |
| Jan 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $153.71 | $153.70 | -0.0% | +0.2% | -0.7% | -0.1% | -0.4% | -0.4% |
| Jan 22 | Barclays | Maintains | Overweight → Overweight | — | $148.56 | $147.63 | -0.6% | -1.0% | +0.0% | +1.3% | +3.5% | +3.6% |
| Oct 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $149.01 | $150.68 | +1.1% | +0.2% | -0.6% | -1.6% | -1.2% | -1.5% |
| Oct 1 | Citigroup | Upgrade | Neutral → Buy | — | $149.01 | $150.68 | +1.1% | +0.2% | -0.6% | -1.6% | -1.2% | -1.5% |
| Aug 2 | Raymond James | Maintains | Outperform → Outperform | — | $145.86 | $146.48 | +0.4% | +2.5% | -0.1% | -0.2% | -1.4% | -0.7% |
| Jul 26 | Stifel | Maintains | Buy → Buy | — | $143.88 | $145.11 | +0.9% | +1.9% | +2.2% | +3.8% | +3.6% | +1.4% |
| Jul 10 | Citigroup | Maintains | Neutral → Neutral | — | $136.88 | $136.84 | -0.0% | +1.1% | +1.6% | +3.4% | +2.1% | +4.2% |
| Jul 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $141.70 | $141.57 | -0.1% | -0.0% | -0.2% | -0.7% | -1.6% | -3.4% |
| May 6 | Barclays | Maintains | Overweight → Overweight | — | $145.05 | $146.36 | +0.9% | +0.8% | +1.0% | -0.5% | +0.1% | +0.4% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $146.60 | $146.47 | -0.1% | -0.9% | +0.6% | +1.0% | +1.5% | +2.8% |
| Jan 3 | Raymond James | Maintains | Outperform → Outperform | — | $151.69 | $151.93 | +0.2% | -2.0% | -1.0% | -1.4% | +0.9% | -3.1% |
| Dec 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $147.25 | $146.67 | -0.4% | -0.3% | -1.9% | -2.0% | -2.0% | -2.5% |
| Nov 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $143.55 | $144.52 | +0.7% | +1.0% | +1.5% | +0.5% | +0.6% | +1.2% |
| Nov 10 | Raymond James | Maintains | Outperform → Outperform | — | $143.55 | $144.52 | +0.7% | +1.0% | +1.5% | +0.5% | +0.6% | +1.2% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $169.16 | $169.01 | -0.1% | +0.7% | +0.7% | +1.2% | +1.2% | +2.3% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $167.37 | $167.74 | +0.2% | +1.6% | +3.8% | +4.0% | +2.4% | +4.2% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $166.07 | $165.79 | -0.2% | +0.8% | +2.4% | +4.6% | +4.8% | +3.2% |
| Aug 4 | Raymond James | Maintains | Outperform → Outperform | — | $166.07 | $165.79 | -0.2% | +0.8% | +2.4% | +4.6% | +4.8% | +3.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Feld MichaelOff | EVP, Chief Revenue Officer | Sell | 74 | $151.94 | $11K | 21,159 | -2.82% | -2.99% |
8-K · 2.02
!! High
Waters Corporation -- 8-K 2.02: Earnings Results
Waters Corporation reported Q2 2026 earnings results for the quarter ending April 4, 2026, providing investors with updated financial performance metrics and operational insights.
May 5
8-K · 5.03
! Medium
Becton, Dickinson and Co. -- 8-K 5.03: Amendment to Articles / Bylaws
Becton, Dickinson and Co. amended its bylaws to change its fiscal year, which may affect dividend schedules, earnings reporting timelines, and investor reporting calendars.
Apr 29
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Rick Byrd's retirement after 25 years as a senior executive signals potential leadership transition risks at BD, though investors should monitor whether succession planning adequately addresses any operational or strategic continuity concerns.
Apr 9
8-K
Unknown — 8-K Filing
Becton Dickinson disclosed non-GAAP financial measures in an 8-K filing, suggesting management may be highlighting adjusted metrics that exclude certain charges, which investors should scrutinize to understand actual operational performance.
Apr 2
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals loses director Lynne Kelley, effective March 2, 2026, potentially affecting board oversight and governance as the company navigates its pharmaceutical development pipeline.
Mar 2
8-K · 8.01
!! High
Becton, Dickinson and Co. -- 8-K 8.01: Material Event / Announcement
Becton, Dickinson announced pricing for its tender offers on February 25, 2026, upsizing the offer cap for 4.685% Senior Notes, allowing investors to sell debt back to the company at predetermined rates.
Feb 25
8-K · 8.01
!! High
Becton, Dickinson and Co. -- 8-K 8.01: Material Event / Announcement
Becton, Dickinson commenced tender offers for its debt securities, providing investors with an opportunity to sell holdings back to the company at specified prices.
Feb 10
8-K
Becton, Dickinson and Co. -- 8-K Filing
BD expects to complete its combination of Biosciences and Diagnostic Solutions businesses with Waters Corporation today, following stronger-than-expected Q1 performance.
Feb 9
8-K
Waters Corp -- 8-K Filing
Waters separated from Becton Dickinson, paying BD $4.0 billion and issuing 38.5 million shares to BD shareholders upon merger completion.
Feb 9
8-K · 7.01
! Medium
Becton, Dickinson and Co. -- 8-K 7.01: Regulation FD Disclosure
Becton, Dickinson completed previously announced transactions as of February 9, 2026, signaling execution of strategic initiatives that may impact shareholder value through operational changes or portfolio adjustments.
Feb 9
8-K · 5.03
! Medium
Becton, Dickinson and Co. -- 8-K 5.03: Amendment to Articles / Bylaws
Becton, Dickinson issued preferred shares via private placement under Securities Act exemption, expanding its capital structure without public registration.
Feb 5
8-K · 7.01
! Medium
Becton, Dickinson and Co. -- 8-K 7.01: Regulation FD Disclosure
Becton Dickinson reorganized into five focused business segments effective October 1, 2025, potentially improving operational clarity and enabling targeted strategy execution for investors monitoring the medical technology company's performance.
Feb 5
8-K
Augusta SpinCo Corp -- 8-K Filing
This boilerplate disclaimer indicates Augusta SpinCo's securities offering remains subject to regulatory approval and registration requirements across jurisdictions before trading can commence.
Feb 5
Data updated apr 24, 2026 9:04pm
· Source: massive.com